More on KPTI

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (6.1 Score)

Upcoming Events

- Earnings (11/3/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Karyopharm Therapeutics (NQ:KPTI)
Delayed: 1.93 +0.02 (1.05%)
Prev. Close $1.91  
Open$1.88 
52 Wk High$19.41 
52 Wk Low$4.83 
Day High$1.95 
Day Low$1.88 
P/E N/A  
EPS$-2.74 
Volume459,191 

Friends, Peers and Foes (?): ARWR, CAPR, CRSP, ALNY, ARVN (more...)

Aug 3, 2026 04:05 PM Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jul 31, 2026 10:31 AM Karyopharm Therapeutics (KPTI) PT Lowered to $11 at Jefferies
Jul 31, 2026 08:35 AM Karyopharm Therapeutics (KPTI) PT Lowered to $7 at Piper Sandler
Jul 31, 2026 08:31 AM Form 8-K Karyopharm Therapeutics For: Jul 30
Jul 31, 2026 06:07 AM H.C. Wainwright Downgrades Karyopharm Therapeutics (KPTI) to Neutral
Jul 31, 2026 03:15 AM Baird Downgrades Karyopharm Therapeutics (KPTI) to Neutral
Jul 30, 2026 04:42 PM Form 4 Karyopharm Therapeutics For: Jul 28 Filed by: Poulton Stuart
Jul 30, 2026 04:08 PM Karyopharm to file myelofibrosis drug application in August 2026
Jul 30, 2026 04:06 PM Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
Jul 30, 2026 04:05 PM Karyopharm's endometrial cancer trial misses primary endpoint
View All Articles

Entities mentioned with KPTI

View All Entities